values obtained before discharge can be plotted on an hour-specific bilirubin nomogram to calculate an infant's bilirubin percentile with respect to age in hours. The predischarge bilirubin "risk zone" (0 -40th, 41st to 75th, 76th to 95th, and Ͼ95th percentile corresponding with low, low-intermediate, high-intermediate, and high risk zones on the hour-specific bilirubin nomogram) has been shown to be a strong predictor of subsequent risk of hyperbilirubinemia. [2] [3] [4] [5] Clinical risk factor assessment involves consideration of an array of maternal, infant, and delivery factors known to be associated with neonatal hyperbilirubinemia. A few studies have formalized the clinical risk factor assessment process by developing scoring systems that incorporate the weighted contribution of multiple risk factors at once. 3, 4, 6 Previous research suggests that the predischarge bilirubin expressed as a risk zone on an hour-specific bilirubin nomogram is more accurate than formal clinical risk factor assessment for determining the risk of developing significant neonatal hyperbilirubinemia. 3, 4 One study has suggested that the addition of clinical risk factors, such as gestational age (GA), can significantly increase the predictive accuracy of the predischarge bilirubin. 4 However, the accuracy of clinical risk factor assessment in these retrospective studies may have been attenuated by omission of important clinical predictors (eg, breastfeeding, severity of jaundice on physical examination, and history of a previous sibling with jaundice or phototherapy). The retrospective nature of these studies may have also resulted in inaccurate risk factor assessment, as well as incomplete and possibly biased sampling of bilirubin measurements.
In this study, we prospectively enrolled a large cohort of newborn infants, performed exhaustive review of clinical risk factors, and systematically measured transcutaneous bilirubin values on nearly all of the enrolled infants throughout the first week of life. Recognizing that many clinicians rely solely on clinical risk factors for assessing the risk of hyperbilirubinemia, we sought to provide comparative data about the predictive properties of the predischarge bilirubin for clinicians considering whether to adopt predischarge bilirubin screening. Cognizant of the fact that clinicians often use both laboratory and history/physical examination data in making clinical decisions, our secondary goal was to describe the incremental predictive value of a risk-assessment strategy that incorporates both clinical risk factors and a predischarge bilirubin value.
METHODS

Design, Setting, and Subjects
This prospective cohort study was conducted in the wellinfant nursery of the Hospital of the University of Pennsylvania (HUP), an urban tertiary care hospital with ϳ3800 deliveries per year. Infants were eligible for enrollment if they were managed exclusively in the well infant nursery and if they were Ն36 weeks' GA and weighed Ն2000 g or if they were Ն35 weeks' GA and weighed Ն2500 g. The birth weight criteria were used to exclude preterm (Ͻ35 week GA) infants who might otherwise be included because of inaccuracies in the estimation of GA. Infants who were transferred to the intensive care nursery for any reason and those who received Ͼ48 hours of intravenous antibiotics for concern for sepsis were excluded from the study.
Recruitment and Sampling Scheme
Because the patient population at HUP is predominantly black, we used a stratified sampling scheme to oversample nonblack infants to assemble a study sample from which results would be more generalizable. Each weekday morning a research assistant compiled a list of infants born in the previous 1 to 2 days stratified by maternal race and used a random number generator to randomize the order of the infants within racial strata. The research assistant then approached parents of infants in the order designated on the list, starting with mothers from race categories of the lowest prevalence at the HUP nursery ("other" category, which included American Indian, Alaskan Native, Native Hawaiian, and Pacific Islander), proceeding to race categories of increasing prevalence (Asian, Hispanic or Latino, white, and black). A maximum of 6 infants were enrolled each day.
Study Protocol
The HUP well-infant nursery adopted universal transcutaneous bilirubin (TcB) screening in June 2004, 3 months before the start of our study. Our study protocol differed only slightly from routine birth hospitalization care in that participants had TcB measurements obtained daily until discharge instead of only 1 routine measurement the night before discharge. TcBs were measured using BiliCheck (Respironics, Murrysville, PA), a Food and Drug Administration-approved noninvasive bilirubinometer. Conforming with the standard of care in the nursery, infants whose TcB measurement exceeded the 75th percentile on an hour-specific bilirubin nomogram 7, 8 had a total serum bilirubin (TSB) measurement obtained. Because the BiliCheck is less accurate at TcB levels Ͼ13 mg/dL (222 mol/L), 8, 9 our protocol also dictated that all TcB values Ն12 mg/dL be confirmed with a TSB. Additional bilirubin measurements and therapeutic interventions (phototherapy or exchange transfusion) were performed during the birth hospitalization at the discretion of the health care team. No decision support was provided as part of the protocol. Also, no additional bilirubin measurements were obtained as part of the study protocol after infants were started on phototherapy.
Bilirubin measurements generally peak at age 3 to 5 days, and so we attempted to obtain bilirubin measurements on all of the study infants in this time frame. If an infant's birth hospitalization was Ͼ72 hours, we obtained at least 1 TcB measurement before discharge between 72 and 120 hours of life. For infants who were discharged from the hospital before 72 hours of life, a study nurse equipped with a BiliCheck device attempted to perform a home visit to obtain a TcB between 72 and 120 hours of life. Similar to the birth hospitalization protocol, the study nurse obtained a heel stick TSB mea-surement if the TcB recorded at the home visit was Ն12 mg/dL (205 mol/L). Decisions to obtain additional bilirubin measurements and to initiate phototherapy after discharge were made by the primary care physicians, who were informed by nurses of all of the TSB values that exceeded the 75th percentile on the hour-specific bilirubin nomogram.
If a high TcB triggered the performance of a TSB (either because the TcB exceeded the 75th percentile before discharge or was Ն12 mg/dL at any time), we used the TSB instead of the TcB for analyses. This ensured that all of the bilirubin values (TcB when TcB was Ͻ12 mg/dL and TSB when TcB was Ն12 mg/dL) were valid measures of TSB.
Predictor Variables
Predischarge bilirubin values used for prediction were those obtained before 52 hours of age. We used an hour-specific bilirubin nomogram 7 to convert the predischarge predictor bilirubin values into risk zones (low, 0-40th percentile; low-intermediate, 41st to 75th percentile; high-intermediate, 76th to 95th percentile; and high, Ͼ95th percentile). For infants who had Ͼ1 bilirubin value obtained before 52 hours of age, we selected the bilirubin value corresponding with the highest risk zone to serve as the predictor value. If the predischarge (Ͻ52 hours) bilirubin corresponding with the highest risk zone also met our criteria for significant hyperbilirubinemia, then that bilirubin served as both a predictor and an outcome value (in which case the predictor predicted the outcome perfectly).
Information on maternal, infant, and delivery characteristics was abstracted from chart review by 2 research assistants. Maternal race, intended method of feeding after discharge (breast, bottle, or both), and history of a previous infant with jaundice or requiring phototherapy were reported by the mother during structured interviews before discharge. GA was abstracted from the obstetric record and was generally estimated from fetal ultrasound or last menstrual period. For the purposes of analysis we rounded GA to the nearest whole week (eg, 37 4 ⁄7 weeks ϭ 38 weeks) and categorized the variable into 3 levels (Ͻ38 weeks, 38 -39 6 ⁄7 weeks, and Ն40 weeks). We used 38 weeks as the first cutoff because we anticipated a discontinuity in the development of significant hyperbilirubinemia at 38 weeks, where the threshold defining significant hyperbilirubinemia jumps to a higher curve. Jaundice assessments to estimate the extent of progression of jaundice were performed on the day after the second night of hospitalization (or the day of discharge if the infant was discharged earlier) to simulate the timing of predischarge decision-making during a typical vaginal birth hospitalization stay. Jaundice assessments were performed by well-infant nursery nurses with Ն2 years of nursery experience who were not caring for the infant being evaluated and were blinded to the infant's bilirubin values. Nurses used the homunculus shown in Fig  1 10 to assess the maximum extent of jaundice on a 5-point scale. The presence of 1 of 5 glucose-6-phosphate dehydrogenase (G6PD) mutations was determined from review of the newborn screen results (Pediatrix, Bridgeville, PA) after hospital discharge. The G6PD mutation analysis included in the Pediatrix screen identifies 5 mutations known to account for Ͼ90% of all affected infants. 11 With the exception of the G6PD mutation result (which is not available until 2 weeks after delivery), all of the information about predictor variables was collected before development of the outcome.
Outcome Variable
Significant hyperbilirubinemia was defined as a bilirubin level (TcB or TSB) that, at any time after birth, exceeded or was within 1 mg/dL (17 mol/L) of the hour-specific phototherapy treatment threshold recommended in the AAP's clinical practice guideline on the management of neonatal hyperbilirubinemia. 1 We included bilirubin levels within 1 mg/dL (17 mol/L) of the treatment threshold in the definition of significant hyperbilirubinemia because, in the absence of a table of threshold values, it is difficult for a clinician to discern the exact hour-specific bilirubin threshold level represented by the phototherapy treatment threshold curves, and, given the expected error around any bilirubin measurement, clinicians may start phototherapy for bilirubin levels short of the treatment threshold by Ͻ1 mg/dL (17 mol/L). Infants who received phototherapy before developing significant hyperbilirubinemia as defined above were classified as not developing the outcome.
We imported the published phototherapy treatment guidelines into Microsoft Visio (Redmond, WA) and used Visio's coordinate plotting function to estimate the hour-specific phototherapy treatment threshold values for all 3 of the treatment threshold curves. We followed the AAP guideline in using specific risk factors for bilirubin neurotoxicity to decide which phototherapy treatment threshold curve to use in determining whether a study infant's bilirubin exceeded the threshold. Because infants with asphyxia, lethargy, temperature instability, sepsis, and acidosis were excluded from the study and G6PD status and albumin level were not known at the time of discharge, the only risk factors that we used to select the appropriate phototherapy treatment threshold curve were GA and Coombs positivity.
Analysis
The primary outcome for this study was the predictive accuracy of alternative strategies for assessing an infant's risk of developing significant hyperbilirubinemia. We compared the predictive accuracy of strategies that use the following: (1) a predischarge bilirubin (obtained at Ͻ52 hours) expressed as a risk zone; (2) multiple clinical risk factors other than the predischarge bilirubin; and (3) a combination of the predischarge bilirubin risk zone and additional clinical risk factors. Overall predictive accuracy was measured using the c-statistic, 12 which is a measure of discrimination-the ability of a test or predictive model to distinguish between patients with and without the outcome of interest (in this case, the development of significant hyperbilirubinemia). The c-statistic is mathematically equivalent to the area under the receiver operating characteristic (ROC) curve 13 for the risk-assessment strategy.
The association between individual risk factors (predictors) and the outcome of interest was estimated using 2 tests and logistic regression. Three logistic regression models were developed to predict the outcome of significant hyperbilirubinemia: (1) a model that included predischarge (Ͻ52 hours) bilirubin risk zone alone; (2) a model that included clinical risk factors other than predischarge bilirubin risk zone; and (3) a model that combined the predischarge bilirubin risk zone and other clinical risk factors. To develop models 2 and 3, we added clinical risk factors individually that were likely to explain variation in the outcome based on their role in the various mechanisms of bilirubin accumulation (increased production, decreased metabolism, and increased enterohepatic circulation) and that were associated with the outcome at a P value Ͻ.05 in bivariate analyses. To remain in the model, the added variables had to continue being significant at a P value Ͻ.05 level. Model calibration was tested using the Hosmer-Lemeshow goodness-of-fit statistic. We plotted ROC curves and calculated and compared the area under the ROC curves for each of the 3 models using an algorithm described by DeLong et al. 14 To estimate the predictive accuracy lost by categorizing the predischarge bilirubin variable into 4 discrete risk zones, rather than treating it as a continuous variable, we used methods suggested by Newman et al 4 to generate a z score associated with each predischarge bilirubin value and calculated the discrimination of the predischarge bilirubin z score for predicting significant hyperbilirubinemia. Likelihood ratios (LRs) were calculated for multilevel risk strata derived from the combination model (model 3).
All of the data were collected by research assistants and entered directly into a Microsoft Access database. Analyses were performed using SAS 9.1 (SAS Institute, Cary, NC) and Stata 8 (Stata Corp, College Station, TX). Informed consent was obtained from mothers of all of the infants in the study. The institutional review boards from the University of Pennsylvania School of Medicine and the Children's Hospital of Philadelphia approved the study protocol.
RESULTS
Subject Characteristics
Between September 2004 and October 2005, 1749 infants were born on days when recruitment occurred. A total of 1079 families (62%) were approached for enrollment in the study and, of those, a total of 823 (76%) consented to participate. Eleven patients were excluded from the study after they developed exclusion criteria (7 transferred to an intensive care nursery, and 4 received antibiotics for Ͼ48 hours), leaving a total of 812 infants. All but 1 of these infants had a bilirubin value obtained before 52 hours (predictor bilirubin value obtained at a mean age of 27 hours; interquartile range [IQR]: 20 -32 hours). We were able to ascertain the development of significant hyperbilirubinemia in 751 infants (92%): 47 (6%) who received phototherapy during the birth hospitalization (mean age at time of initiation: 43 hours; IQR: 27-51 hours) and 704 (87%) who did not receive phototherapy during the birth hospitalization and had a bilirubin value obtained between 72 and 192 hours (mean age: 97 hours; IQR: 82-120 hours). Sixty-one infants (7%) were lost to follow-up and did not have birth hospitalization phototherapy or a bilirubin obtained after 72 hours (Fig 2) . Table 1 lists the maternal, pregnancy and delivery, and infant characteristics of the study sample. Our sampling scheme resulted in 47% of the study sample being nonblack compared with the 37% of nonblack mothers who delivered during days on which we recruited. The intended method of feeding for 468 infants (57%) was exclusively breast or combined breast and bottle. A total of 191 infants (24%) were delivered by cesarean section, and 109 infants (13%) were Ͻ38 weeks GA. Jaundice assessments were completed on 744 infants (92%; mean age at time of assessment: 48 hours; IQR: 41-54 hours), 4% of whom had grade 4 or higher jaundice. Infant blood type and Rhesus status were not known for the majority of infants. G6PD DNA analysis results were retrieved for all of the infants, 4% of whom had 1 of the 5 G6PD enzyme mutations that are detected by the screen.
Predictors of Significant Hyperbilirubinemia
Forty-eight infants (6%) developed significant hyperbilirubinemia (ie, had bilirubin levels exceeding [n ϭ 24] or within 1 mg/dL [n ϭ 24] of the phototherapy treatment threshold). Forty-four (92%) of the 48 infants who developed significant hyperbilirubinemia received phototherapy (33 before, 10 after, and 1 both before and after discharge from the birth hospitalization). Fifteen infants were found to develop significant hyperbilirubinemia in the first 52 hours, 9 at the time of the first bilirubin measurement. In these instances the predischarge bilirubin was considered to predict the outcome perfectly. Twenty-three infants received phototherapy without meeting our definition of significant hyperbilirubinemia (13 before and 10 after discharge) and, therefore, were not considered to have developed the outcome.
Infant, maternal, and pregnancy/delivery characteristics from Table 1 that were associated with the development of significant hyperbilirubinemia at a P value level Ͻ.05 are listed in Table 2 . The factor most strongly associated with development of significant hyperbilirubinemia was the predischarge bilirubin risk zone. None of the 218 infants with predischarge bilirubins in the low-risk zone developed significant hyperbilirubinemia, and only 2 (1%) of the infants with predischarge bilirubins in the low-intermediate risk zone developed significant hyperbilirubinemia. Compared with infants who had predischarge bilirubins in the low or low-intermediate risk zones, the odds ratio (OR) for developing significant hyperbilirubinemia among infants with predischarge bilirubin levels in the high-intermediate and high-risk zones was 21 (95% confidence interval [CI]: 4.9 -93.0) and 147 (95% CI: 34 -639), respectively. GA Ͻ38 weeks (OR: 9.2; 95% CI: 4.4 -19) and breastfeeding were also strongly associated with development of significant hyperbilirubinemia. Mother's stated intention to give both breast and bottle feeds (OR: 3.7; 95% CI: 1.6 -8.6) was more strongly associated with the outcome than a stated plan to breastfeed exclusively (OR: 2.2; 95% CI: 1.0 -4.5). Grade 4 or higher jaundice was also strongly associated with the development of significant hyperbilirubinemia (OR: 6.0; 95% CI: 2.1-17.0). In analyses stratified by race, the association between grade 4 or higher jaundice and development of significant hyperbilirubinemia was present only for nonblack infants (OR: 6.9; 95% CI: 2.2-22.0). Black infants did not demonstrate this association: 7 of 353 black infants with grade 0 to 3 jaundice developed significant hyperbilirubinemia, whereas 0 of 10 with grade 4 or higher jaundice did (OR: not calculable; P ϭ .81). Interestingly, of the 140 infants (both black and nonblack) who had no jaundice noted (jaundice score ϭ 0), only 2 developed significant hyperbilirubinemia (negative predictive value ϭ 98.6%), both of whom were white and had a predischarge bilirubin in the high-intermediate (n ϭ 1) and high-risk (n ϭ 1) zones. A positive G6PD DNA analysis was not associated with the development of significant hyperbilirubinemia in either the entire sample (OR: 0.99; 95% CI: 0.23-4.3) or in the subgroups of male infants, black infants, or black male infants. Factors associated with a decreased risk of significant hyperbilirubinemia included black race (OR: 0.43; 95% CI: 0.23-0.80) and maternal history of smoking during the pregnancy.
Comparing Risk-Assessment Strategies
We built a multivariable logistic regression model to predict development of significant hyperbilirubinemia
FIGURE 2
Enrollment and follow-up of study subjects. a Twenty three of the 703 infants classified as not developing the outcome of significant hyperbilirubinemia received phototherapy without a bilirubin level that met our criterion for significant hyperbilirubinemia.
using clinical risk factors other than the predischarge bilirubin risk zone. The final model included 5 variables: GA, intended method of feeding, black race, extent of jaundice, and gender (c-statistic ϭ 0.91; 95% CI: 0.86 -0.97; Hosmer-Lemeshow goodness-of-fit test P ϭ 0.71). The predictive performance of a logistic regression model that included only the predischarge bilirubin risk zone was not significantly different from the 5 variable clinical risk factor model (c-statistic ϭ 0.88; 95% CI: 0.85-0.91; P for difference ϭ 0.35; Hosmer-Lemeshow goodnessof-fit test P Ͼ 0.99). Expressing the predischarge bilirubin as a z score as opposed to a 4-level risk zone improved its predictive accuracy (c-statistic ϭ 0.92; 95% CI: 0.89 -0.95; P for difference Ͻ .0001; Hosmer-Lemeshow goodness-of-fit test P ϭ .52). The only clinical risk factors that remained statistically significant when added to the predischarge bilirubin risk zone in a "combination" model were GA and percentage of weight loss per day. The predictive performance of the combination model (c-statistic ϭ 0.96; 95% CI: 0.93-0.98; HosmerLemeshow goodness-of-fit test P ϭ 0.99) was better than that of the predischarge bilirubin used alone (P for difference Ͻ .001), as well as the 5-variable clinical risk factor model (P for difference ϭ 0.15), although the difference for the latter comparison did not reach statistical significance. The ROC curves for these 3 predictive models are plotted in Fig 3. The results of these comparisons were relatively consistent under varying assumptions regarding the definition of our predictor and outcome variables. For example, excluding the 15 infants from the analysis whose predischarge bilirubin also met the criterion for significant hyperbilirubinemia slightly decreased the accuracy of the predischarge bilirubin risk zone (c-statistic ϭ 0.85) but did not change the accuracy of the clinical risk factor model (c-statistic ϭ 0.90) or the combination model (c-statistic ϭ 0.95). Excluding infants who received phototherapy before meeting the outcome criterion did not significantly change the predictive accuracy of the 3 models (c-statistic ϭ 0.89, 0.91, and 0.96, respectively). Counting these infants as having met the outcome criterion also did not significantly change the predictive accuracy of the predischarge bilirubin and combination model (c-statistic ϭ 0.89 and 0.95, respectively) but did decrease the accuracy of the clinical risk factor model (c-statistic ϭ 0.88). Although all of the factors in the combination model were statistically significant, we found that the only added variable that increased the model's predictive accuracy above that derived from the predischarge bilirubin risk zone alone was GA (c-statistic ϭ 0.952 vs 0.954 for the full model). To illustrate how GA contributed to the predictive performance of the predischarge bilirubin, we calculated the proportion of infants who developed significant hyperbilirubinemia stratified by these 2 parameters (Fig 4) . The figure shows that, for children with predischarge bilirubins in the high-intermediate or highrisk category, GA Ͻ38 weeks increases the risk of significant hyperbilirubinemia several fold. Figure 5 demonstrates how information on the predischarge bilirubin risk zone and GA can be used to classify infants into 1 of 3 distinct groups in terms of their risk of developing significant neonatal hyperbilirubinemia (very low risk: 0.2%, LR: 0.028; low risk: 4.0%, LR: 0.600; and high risk: 42.0%, LR: 10.600).
DISCUSSION
A risk-assessment strategy that incorporated clinical risk factors from the history and physical examination had predictive accuracy similar to that of the predischarge (Ͻ52 hours) bilirubin risk zone used alone, the difference in the area under the ROC curves stemming mostly from the paucity of points on the predischarge bilirubin risk zone curve. Expressing the predischarge bilirubin as a continuous variable (z score), rather than a categorical one, resulted in a smoother curve with a slightly higher area under it. A risk-assessment strategy that combined the predischarge bilirubin risk zone and a few clinical risk factors had better overall predictive accuracy than strategies that used the clinical risk factors or predischarge bilirubin risk zone alone (although the increase in accuracy over the clinical risk factor model did not reach statistical significance, likely because of the limited sample size). In developing this "combination model" we found that GA was the only clinical risk factor that, when added to the predischarge risk zone, significantly improved overall predictive accuracy. Our analyses suggest that knowledge of just these 2 easily obtained and objectively determined factors can help a clinician to stratify patients into 3 distinct risk categories. Infants in the "very low" risk category can be followed clinically and may be spared follow-up bilirubin measurements, assuming the physical examination and history do not change dramatically to warrant a repeat bilirubin measurement. Infants in the "low" risk category can also be managed expectantly, but the threshold for performing a follow-up bilirubin may be a little lower than for the "very low" risk group. Finally, the infants who are categorized as "high" risk, depending on the height of their predischarge bilirubin, may warrant initiation of phototherapy according to AAP treatment guidelines, a follow-up bilirubin in 24 hours, or delayed discharge from the birth hospitalization if follow-up cannot be guaranteed.
Our results are fairly consistent with those reported by other investigators. Although defined differently across studies, significant hyperbilirubinemia has repeatedly been shown to be associated with the predischarge bilirubin risk zone, [3] [4] [5] 7 GA Ͻ38 weeks, 2-4,6,15 and breastfeeding. [2] [3] [4] [5] [6] 16 Similar to the study by Newman et al 6 on clinical risk factors for significant hyperbilirubinemia, we also found black race to be protective, but, unlike in that study, female gender was associated with an increased, rather than decreased, risk of hyperbilirubinemia in our subjects. Consistent with previous studies, 3, 4 we found that risk-assessment strategies that combine multiple clinical risk factors (other than the predischarge bilirubin) have similar (but not better) accuracy than a strategy that relies on the predischarge bilirubin value alone. Similar to Newman et al, 6 we also found that, after the predischarge bilirubin risk zone, GA was the strongest predictor of significant hyperbilirubinemia and could be used in combination with the predischarge risk zone to stratify infants into distinct risk categories. Interestingly, some of the factors listed as major risk factors in the AAP Practice Guideline on Management of Neonatal Hyperbilirubinemia were not found to be significant predictors of significant hyperbilirubinemia in our study, including the presence of cephalohematoma (OR: 1.8; 95% CI: 0.63-5.40) or bruising (OR: 1.5; 95% CI: 0.44 -5.10) and a history of a sibling who received phototherapy (OR: 1.1; 95% CI: 0.46 -2.70), although the OR point estimates and 95% CIs are consistent with those reported previously for these variables.
Our study is the first to prospectively ascertain clinical risk factors and to compare alternative strategies for assessing the risk of significant hyperbilirubinemia. Its prospective nature allowed us to perform an exhaustive review of potential clinical risk factors, including historical factors, such as a history of a previous child with jaundice or requiring phototherapy and self-reported maternal race. The availability of a study nurse to visit infants at home after discharge enabled us to perform bilirubin measurements during the time that bilirubin values peak on nearly all of the study infants, and, thus, avoided the potential for verification bias that was present in previous retrospective studies. Our study is also the first to incorporate a formal assessment of the extent of jaundice before discharge as a predictor of significant hyperbilirubinemia. Although the extent of jaundice did not add to the predictive accuracy of the predischarge bilirubin risk zone, it did remain significant in the multivariable clinical risk factor model. The fact that grade 4 or higher jaundice was predictive of subse- 
FIGURE 4
Probability of significant hyperbilirubinemia given predischarge bilirubin and GA. quent significant hyperbilirubinemia only in nonblack infants supports the notion that the presence and degree of jaundice may be more difficult to discern in infants with darker skin pigmentation. 17, 18 Interestingly, the complete absence of jaundice (grade 0) had high negative predictive value (98%) for subsequent significant hyperbilirubinemia in both black and white infants. Finally, our study is the first to evaluate the relationship between the results of DNA-based screening for G6PD deficiency and the development of significant hyperbilirubinemia. Our results suggest that even if the DNA-based test result could be made available before discharge, it may not be helpful in predicting the risk of hyperbilirubinemia requiring phototherapy, even in subgroups of male, black, or black male infants. Scenarios that may compromise the predictive accuracy of DNA-based G6PD deficiency testing include detected mutations associated with adequate enzyme levels, detected mutations that result in low enzyme activity levels but not hyperbilirubinemia, and undetected mutations that result in low enzyme activity and hyperbilirubinemia. 11 Further investigation is needed to determine the role of G6PD mutation analysis, as well as alternative (G6PD enzyme level measurement 19, 20 ) and supplementary (UDPGT1 polymorphism 21 ) testing for identifying infants who need close monitoring for the risk of hemolysis, severe hyperbilirubinemia, and possibly kernicterus related to G6PD deficiency.
Our study had a few limitations. Our sample size allowed us to detect only risk factors that were strongly associated with the outcome of interest or that were prevalent. We were reassured, however, that the only factor that added significantly to the predictive accuracy of the predischarge bilirubin risk zone, GA, is the one that is most strongly associated with the predicted outcome. Second, some infants were started on phototherapy before meeting our outcome criterion, which prevented us from determining whether they would have developed the outcome of interest. However, sensitivity analyses demonstrated no major differences in the relative accuracy of the 3 evaluated strategies when these infants were excluded or treated as having developed the outcome. Finally, despite our attempts to oversample infants of nonblack race, approximately half of the study infants were born to black mothers. If, as suggested by our data, black race is associated with a lower risk of significant hyperbilirubinemia, then patient populations with fewer black infants may have higher rates of significant hyperbilirubinemia, both overall and in various risk strata, than reported in our study.
CONCLUSIONS
Strategies that use either clinical risk factors or predischarge bilirubin values to assess the risk of significant hyperbilirubinemia have similar predictive accuracy, although studies are needed to prospectively validate the accuracy and reliability of specific clinical risk factor prediction rules. The most accurate risk-assessment strategy incorporates information about both predischarge bilirubin values and clinical risk factors, specifically GA. Knowledge of just these 2 factors provides a simple and accurate way to assess an infant's risk of developing significant hyperbilirubinemia.
Future research on risk-assessment strategies for significant hyperbilirubinemia will need to identify the actions that should be taken given the predicted risk and quantify the "cost" of the "errors" in risk assessment (both false-positives and false-negatives) in terms of unnecessary testing and treatment, delay in discharge, and the occurrence of extreme hyperbilirubinemia and kernicterus. Given the low incidence of kernicterus, economic evaluation of risk-assessment strategies will have to rely on mathematical models in addition to empiric studies. The implementation of strategies that use universal bilirubin screening is associated with a reduced risk of extreme hyperbilirubinemia. 22 Fine tuning the appropriate response to a predischarge bilirubin value will help ensure that universal bilirubin screening will also be cost-effective and minimally invasive. Risk of significant hyperbilirubinemia according to predischarge bilirubin percentile and GA.
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